UA137864U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (PSP), homocysteine. At homozygous carrier 677-TT and levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (AN Okorokov. Diagnostics of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, according to a useful model, the patient's blood serum additionally determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (SRP), homocysteine and homozygous carrier 677-TT, and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l, homocysteine 220 μmol/l predict the development osteoarthritis

The method is used as follows.

During hospitalization, the patient is examined, x-rays are taken, and the MTNEV C677T gene polymorphism is determined. The content of thrombomodulin, folic acid, oxyproline, SRP, homocysteine is determined by immunoenzymatic method. With homozygous carrier 677-117, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline "15 μmol/l, SRP "b mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient O., 66 years old, was hospitalized in the clinic due to pain in the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found.

Polymorphism of MTNEV C677T gene was determined in blood serum. The content of thrombomodulin, folic acid, oxyproline, SRP, homocysteine was determined by immunoenzymatic method.

Zo Homozygous carrier 677-TT was established. Levels of thrombomodulin - 15 ng/ml, folic acid - 3.9 ng/ml, oxyproline - 28 μmol/l, SRP - 16 mg/l, homocysteine - 30 μmol/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the patient's blood serum additionally determines the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEV C677T), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (CRP) , homocysteine, and with homozygous carrier 677-TT, and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "b mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.